Platelet activation is increased in cyclosporin A-induced hypertensive rats.
One of the most severe side effects of the immunosuppressive agent, cyclosporin A (CsA), is increased risk of thromboembolic complications and drug-related hypertension. Because platelets might be involved in these processes, we tested the possibility of CsA affecting platelet activation, which might contribute to these adverse drug reactions. The experiments were done using Wistar rats, treated or not (control) with CsA (Sandimmun Neoral), 5 and 30 mg/kg/day, for 7 weeks. Systolic, diastolic, and mean blood pressures, intracellular free calcium concentration ([Ca2+]i), platelet serotonin (5-HT) contents, and aggregation were determined, at weeks 0, 2, and 7 of treatment. Inositol phosphates (InsP) production, platelet thromboxane A2 (TXA2) generation, and morphology of platelets, through electron microscopy studies, also were compared. It was demonstrated that blood pressures increased in the CsA-treated groups, when compared with the control group, after 2 and 7 weeks of administration. CsA at both "attack" and "maintenance" doses increased basal, 5-HT, and thrombin-evoked [Ca2+]i after 2 and 7 weeks versus the control group. However, basal and evoked InsP production was stimulated by 5 mg/kg of CsA, but inhibited by 30 mg/kg, when compared with the control. Platelet 5-HT contents decreased significantly after 2 and 7 weeks in the CsA-treated groups, when compared with the control group. Collagen-induced whole blood platelet aggregation increased drastically in the "attack" CsA-treated group, whereas adenosine diphosphate (ADP)-induced platelet aggregation did not reach statistical significance. Finally, in vitro basal, collagen-, and ADP-evoked platelet TXA2 generation increased in both CsA concentrations, versus the control. In conclusion, our study demonstrates that both CsA doses alter platelet calcium homeostasis (even affecting the calcium fluxes differently), 5-HT and TXA2 contents and aggregation, which might contribute to the development and/or maintenance of high blood pressures and increased risk of thromboembolic complications.
Reis
F
F
Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine University of Coimbra, Portugal.
Tavares
P
P
Rito
L C
LC
Teixeira
H M
HM
Santos Dias
J D
JD
Ferrer-Antunes
C
C
Mesquita
J F
JF
Teixeira
F
F
D000818:Animals; D002118:Calcium / Q000378:metabolism*; D016572:Cyclosporine / Q000009:adverse effects / Q000494:pharmacology*; D006973:Hypertension / Q000139:chemically induced / Q000378:metabolism*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology*; D007295:Inositol Phosphates / Q000378:metabolism; D008297:Male; D015539:Platelet Activation / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D012701:Serotonin / Q000097:blood; D013928:Thromboxane A2 / Q000378:metabolism
D007166:Immunosuppressive Agents; D007295:Inositol Phosphates; D012701:Serotonin; D013928:Thromboxane A2; D016572:Cyclosporine; D002118:Calcium